Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
Indian American researcher developing a novel type of living T cell-based therapy to tackle obesity-induced diabetes ...
2d
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...
Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...
Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results